Enhanced Galectin-1 for Inflammatory Muscular Diseases and Autoimmune Disorders ID: 2021-045
An innovative treatment utilizing modified recombinant human Galectin-1 to significantly improve outcomes in muscular dystrophies and autoimmune conditions.
Photo by starlineart - stock.adobe.com
Technology Overview
This technology centers on a modified form of recombinant human Galectin-1 (rHsGal-1), specifically engineered with a 6X-His Tag for simplified purification and detection. It is designed to enhance membrane repair, reduce inflammation, and boost myogenic potential in models lacking dysferlin, a crucial protein in muscular dystrophy. The approach not only addresses the underlying issues of membrane instability in muscular diseases but also offers a novel pathway for treating autoimmune disorders by modulating the immune response.
Key Advantages
- Enhanced mechanical stabilization during membrane repair
- Increased myogenic potential, aiding muscle regeneration
- Improved mobility in experimental models
- Boosted secretion of anti-inflammatory cytokines, such as IL-4
Problems Addressed
- Insufficient membrane repair in muscular dystrophies
- High levels of inflammation in autoimmune and muscular diseases
- Limited treatment options for autoimmune disorders and muscular dystrophies
Market Applications
- Treatment for various forms of muscular dystrophy and autoimmune diseases
- Research tool in muscle regeneration and autoimmune disorder studies
- Potential for development into therapeutic drugs by biotechnology and pharmaceutical companies
Additional Information
Technology ID: 2022-002
Sell Sheet: Download the Sell Sheet here
Market Analysis: Contact us for a more in-depth market report
Date Published: 28 March, 2025
Connect with the Tech Transfer to:
- Meet with the technology manager
- Receive additional information
- Request a marketing plan report